

# Serotonin suppresses slow oscillations by activating somatostatin interneurons via the 5-HT<sub>2A</sub> receptor

Roberto De Filippo<sup>1</sup>, Benjamin R. Rost<sup>2</sup>, Alexander Stumpf<sup>1</sup>, Claire Cooper<sup>1</sup>, John J. Tukker<sup>1,2</sup>, Christoph Harms<sup>3-5</sup>, Prateep Beed<sup>1</sup>, Dietmar Schmitz<sup>1,2,5\*</sup>

<sup>1</sup> Charité – Universitätsmedizin Berlin, Neuroscience Research Center, 10117 Berlin, Germany

<sup>2</sup> German Centre for Neurodegenerative Diseases (DZNE), 10117 Berlin, German

<sup>3</sup> Charité – Universitätsmedizin Berlin and Berlin Institute of Health, Department of Experimental Neurology, 10117 Berlin, Germany.

<sup>4</sup> Charité – Universitätsmedizin Berlin, Center for Stroke Research Berlin, 10117 Berlin, Germany

<sup>5</sup> Charité – Universitätsmedizin Berlin, Einstein Center for Neurosciences Berlin, 10117 Berlin, Germany

\* Correspondence to: [dietmar.schmitz@charite.de](mailto:dietmar.schmitz@charite.de)

**Keywords:** serotonin, 5-HT<sub>2A</sub>, somatostatin interneurons, slow oscillations, MDMA, entorhinal cortex

## Abstract

Serotonin (5-HT) affects multiple physiological processes in the brain and is involved in a number of psychiatric disorders. 5-HT axons reach all cortical areas; however, the precise mechanism by which 5-HT modulates cortical network activity is not yet fully understood. We investigated the effects of 5-HT on slow oscillations (SO), a synchronized cortical network activity universally present across species. SO are observed during slow-wave sleep and anesthesia and are considered the default cortical activity pattern. Combining opto- and pharmacogenetic manipulations with electrophysiological recordings, we discovered that 5-HT inhibits SO within the entorhinal cortex (EC) by activating somatostatin-expressing (Som) interneurons via the 5-HT<sub>2A</sub> receptor (5-HT<sub>2A</sub>R). This receptor is involved in the etiology of different psychiatric disorders and mediates the psychological effects of many psychoactive serotonergic drugs, suggesting that 5-HT targeting of Som interneurons may play an important role in these processes.

# Introduction

5-HT is one of the most important neuromodulators in the central nervous system. Projections originating from the Raphe nuclei, the brain-stem structure that comprises the majority of 5-HT releasing neurons in the brain, reach all cortical and sub-cortical area (Descarries et al., 2010). Consequentially, it is not surprising that 5-HT is involved in the regulation of a myriad of physiological functions (e.g. circadian rhythm, mood, memory formation, reward encoding, sexual behavior) and psychiatric disorders including depression, autism, schizophrenia, and anxiety disorders (Monti, 2011, Underwood et al., 2018, Hayes and Greenshaw, 2011, Teixeira et al., 2018, Uphouse and Guptarak, 2010, Nakai et al., 2017).

5-HT levels in the brain are closely linked to the sleep-wake cycle. Activity of serotonergic raphe neurons is increased during wakefulness, decreased during slow-wave sleep and virtually silent during REM sleep (McGinty and Harper, 1976, Oikonomou et al., 2019). Cortical activity is also influenced by the behavioral state of the animal: slow-wave sleep (SWS) is generally associated to “synchronized” patterns of activity, characterized by low-frequency global fluctuations, whereas active wakefulness and REM sleep features “desynchronized” network activity in which low-frequency fluctuations are absent. The shifting of cortical networks between different patterns of activity is controlled, at least in part, by neuromodulators (Lee and Dan, 2012). For instance, Acetylcholine (Ach) can profoundly alter cortical network activity by inducing desynchronization via activation of Som interneurons (Chen et al., 2015). However, it is not solely responsible for cortical desynchronization as lesions of cholinergic neurons are not sufficient to abolish desynchronization (Kaur et al., 2008). On the other hand, blocking Ach and 5-HT transmission at the same time causes a complete suppression of cortical desynchronization, even during active behavior, thus suggesting that 5-HT plays an important role in desynchronization (Vanderwolf and Baker, 1986). In agreement with this line of thought, electrical and optogenetic stimulation of the Raphe nuclei reduce low frequency (1-10 Hz) power in the cortex thus promoting desynchronization (Puig et al., 2010, Grandjean et al., 2019). Moreover, optogenetic stimulation of serotonergic neurons at a physiological frequency (25 Hz) is sufficient to wake up mice from SWS (Oikonomou et al., 2019). These data suggest a causal relationship between 5-HT levels and cortical activity (Lee and Dan, 2012, Harris and Thiele, 2011). The exact mechanism by which 5-HT modulates network activity in the cortex is, however, still not fully understood.

Here, we used electrophysiological techniques together with pharmacology, optogenetics and pharmacogenetics to investigate the effect of 5-HT on SO, a network oscillation


characterized by synchronized transitions ( $< 1$  Hz) between periods of high activity (up-state) and relative quiescence (down-state) (Steriade et al., 1993, Neske, 2015). SO are a global phenomenon observed throughout the cerebral cortex and are considered to be the default emergent activity of cortical networks during slow wave-sleep and anesthesia (Neske, 2015, Sanchez-Vives et al., 2017). Our results show that 5-HT release *in vivo* is sufficient to suppress SO and, concurrently, activate a small group of neurons characterized by an intermediate waveform shape. Using cortical brain slices, we were able to characterize the 5-HT activated neurons as Som-expressing interneurons and show that they are necessary mediators of the effect of 5-HT on SO *in vitro*. While previous studies have shown that parvalbumin (PV) interneurons are excited by 5-HT (Puig et al., 2010, Athilingam et al., 2017), our results identify cortical Som interneurons as novel targets of the 5-HT neuromodulatory system.

## Results

### 5-HT inhibits SO *in vivo*

We investigated the effect of 5-HT on network activity in anesthetized mice using multisite silicon microelectrodes placed in the entorhinal cortex (EC), a region located in the medial temporal lobe interconnected to a variety of cortical and subcortical areas (Figure 1A-B, Figure 1-figure supplement 1) including the Raphe nuclei (Figure 1C) (van Strien et al., 2009, Muzerelle et al., 2016). Under urethane anesthesia, EC, like the rest of the cortex, displays SO (Figure 1-figure supplement 2). As expected, we found that up-states were present synchronously in the local field potential (LFP) of all the recording channels (Figure 1-figure supplement 3) and every up-state coincided with large increases in population spiking activity (Figure 1D). 5-HT does not cross the blood brain barrier (Hardebo and Owman, 1980), therefore, to understand the effect of 5-HT on SO we used ( $\pm$ )3,4-methylenedioxymethamphetamine (MDMA), a potent presynaptic 5-HT releaser and popular recreational drug (Green et al., 2003). Intraperitoneal injections of MDMA (1.25 mg/kg) caused a strong suppression of up-state incidence (Figure 1G-J), a decrease in power of delta frequencies (Figure 1H), and a reduction of population spiking activity (Figure 1I-K). MDMA also causes, although to a lesser extent, the release of dopamine and noradrenaline (Green et al., 2003). To test whether the effect of MDMA was mediated specifically by 5-HT we repeated the experiment using fenfluramine (Fen) (5 mg/kg), a more selective 5-HT releaser (Rothman and Baumann, 2002). Intraperitoneal injection of Fen had a comparably strong suppressive effect on both the occurrence of up-states and


population spiking activity (Figure 1J-K). This shows that 5-HT released from raphe neurons is capable of modulating ongoing oscillatory activity and suppress low-frequency fluctuations.



**Figure 1| MDMA inhibits SO *in vivo*.** (A) Map of EC output connectivity registered to the Allen mouse common coordinate framework. Circle size represents projection energy (see “Supplementary Materials and Methods”). Circle color encodes area location according to the Allen institute standard: green = cerebral cortex, blue = cerebral nuclei, pink = midbrain, red = interbrain/hindbrain and yellow = cerebellum. (B) Scatter plot showing relationship between projection distance and projection energy. (C) Immunostaining of an ePet-YFP mouse showing serotonergic fibers in medial entorhinal cortex, horizontal slice (M = medial, L = lateral, P = posterior, A = anterior). Scale bar: 20 μm. (D) LFP (top) and instantaneous population activity (bottom) of a representative *in vivo* recording during SO (spikes/s units in thousands), cyan rectangles represent detected up-states. (E) 3D visualization of the microelectrode location of the recording shown in G. EC represented in grey. (F) Left: microelectrode tracks (red) of the recording shown in (G). Right: EC position represented in green. (G) Top: Cyan lines represent detected up-states. Bottom: LFP (black) and average up-state incidence per minute (cyan). Pink dotted line represents MDMA application time. (H) Fourier transformation and (I) instantaneous population activity for the recording shown in G (spikes/s units in thousands). (J) Mean up-state incidence after saline (control), Fen or MDMA application (control: n = 5, Fen: n = 6, MDMA: n = 7;  $p < 10^{-4}$ , unpaired t test with Holm-Sidak correction). (K) Mean normalized spike rate after saline (control), Fen or MDMA application (control: n = 5, Fen: n = 6, MDMA: n = 7;  $p < 10^{-4}$ , unpaired t test with Holm-Sidak correction).

## 5-HT activates a subgroup of cortical neurons

Besides the LFP signal, we recorded the activity of 355 single units within the EC. Because of the very similar effects of MDMA and Fen on spike rates (Figure 1K), we pooled all units recorded in both types of experiments. We found that drug injections differentially affected



**Figure 2| Divergent unit responses to MDMA/Fen application.** (A) Spike rate of the activated units versus all the other units during MDMA/Fen application (activated:  $n = 31$ , Non-activated:  $n = 324$ ). (B) Top: TP latencies color-coded by group. Middle: cumulative distribution of TP latencies (Kolmogorov-Smirnov test,  $p_{\text{Activated vs Int}} < 10^{-4}$ ,  $p_{\text{Activated vs Exc}} < 10^{-4}$ ). Bottom: bar plot representing probability distribution of TP latencies, on the right y axis dashed line representing the percentage of ‘activated’ units per TP latency bin. (C) Distribution of units according to trough-to-peak (TP) latencies and repolarization time, units were classified as putative interneurons (Int, blue) and putative excitatory (Exc, dark gray) according to a threshold at 0.55 ms; activated units (red) could belong to either group but were mostly intermediate as shown by the covariance (2 STD) of each group (Ellipses). Units recorded during control experiments are represented by empty circles. (D) Waveforms of recorded units ( $n = 355$ ). Units were divided into “putative excitatory” (black) and “putative inhibitory” (blue) neurons according to TP latencies. Units activated either by MDMA or Fen application are represented in red. Inset shows the average waveform for each group. Scale bars: 0.5 ms.

spiking rates (Figure 2A) of recorded units: while spiking decreased in the majority of units (‘non-activated’), a small group of units (‘activated’) responded in the opposite fashion ( $n=31/355$ , 8.7%).




Trough-to-peak (TP) latency of the spike waveform has been consistently used as a metric to classify units and, in accordance with previous studies (Senzai et al., 2019, Roux et al., 2014), we found a clear bimodal distribution of TP latencies distinguishing putative excitatory (Exc) and fast-spiking inhibitory (Int) groups. Analysis of cross-correlograms to infer monosynaptic connections confirmed the inhibitory nature of a subset of putative FS units (Figure 2–figure supplement 1) (Barthó et al., 2004). The cumulative distribution of TP latencies of ‘activated’ units was significantly different to both Exc and Int groups (Figure 2B). Specifically, the average TP latency of ‘activated’ units was situated in between the Int and Exc groups (Figure 2B-D, Figure 2–figure supplement 2), possibly suggesting a non-fast spiking interneuron identity (Trainito et al., 2019, Kvitsiani et al., 2013).

### 5-HT suppresses SO and activates Som interneurons *via* 5-HT<sub>2A</sub>R

To understand the mechanism underlying the suppression of SO by 5-HT we combined electrophysiology and pharmacology *in vitro*. First, we recorded simultaneously from up to four neurons in the superficial layers of the EC (Figure 3A). Brain slices were perfused with an extracellular solution containing Mg<sup>2+</sup> and Ca<sup>2+</sup> in concentrations similar to physiological conditions. With this method we could reliably detect SO reminiscent of the *in vivo* network activity (Tahvildari et al., 2012). Release of 5-HT *in vitro*, induced by Fen application, caused a suppression of SO similar to what we observed *in vivo* (Figure 3–figure supplement 1). Likewise, application of low concentrations of 5-HT (5 μM) caused a suppression of SO (Figure 3B, C). This effect was highly consistent across different slices and was readily reversible (Figure 3D). Similarly to spontaneous up-states, electrically evoked up-states (Neske et al., 2015) were also suppressed by 5-HT (Figure 3–figure supplement 2). Increasing the stimulation intensity did not rescue up-state generation, indicating that lack of excitation alone cannot explain the suppressive effect of 5-HT on SO.

Suppression of activity can have either an intrinsic or synaptic origin (Turrigiano, 2011). A substantial subset of EC excitatory neurons is known to express 5-HT<sub>1A</sub> receptor (5-HT<sub>1A</sub>R) and hyperpolarize upon 5-HT application via activation of G protein-coupled inwardly-rectifying potassium (GIRK) channels (Figure 3–figure supplement 3E) (Schmitz et al., 1998, Chalmers and Watson, 1991). SO suppression, however, was not influenced by blocking 5-HT<sub>1A</sub>R (Figure 3–figure supplement 3A, F). In contrast, blocking 5-HT<sub>2A</sub>R with the selective antagonist ketanserin (Preller et al., 2018) strongly reduced the suppression power of 5-HT on SO from 95 ± 4% to 57 ± 10.1% (Figure 3–figure supplement 3B, F). The remaining suppression can be possibly explained by the activation of 5-HT<sub>1A</sub>R on excitatory cells, this is reflected by the



**Figure 3| 5-HT suppresses SO and activates Som interneurons.** (A) Biocytin staining of four simultaneously recorded cells shown in (B) WFS1 expression (in red) delimits L2/3 border. (B) Intracellular recordings showing synchronous up-state events in 4 simultaneously recorded cells before (left) and after (right) 5-HT application. Scale bars: 1: 7.5 mV, 2: 25 mV, 3: 25 mV, 4: 10 mV; 10 s. (C) Up-state raster plot before and after 5-HT application, orange box represents 5-HT application ( $n = 17$ ,  $p < 10^{-4}$ , Wilcoxon signed rank test). (D) Representative recording showing the temporary inhibitory effect of 5-HT on SO in two simultaneously recorded cells. Scale bars: 5 min, 20 mV. (E) PCA projection plot of all the cells recorded ( $n = 48$ ). Cells are color coded according to group identity: Exc (black), FS (light blue) or LTS (green). Typical voltage responses to current injection (-150 and +250 pA) are plotted for each group. (F) Representative recording of an excitatory (black) and a low-threshold (green) neuron simultaneously recorded during 5-HT application. Scale bars: 10 mV, 30 s. (G) Average change of RP before and after 5-HT application, across excitatory, fast-spiking and low-threshold neurons (Exc:  $n = 34$ , FS:  $n = 6$ ; LTS:  $n = 9$ ;  $p < 10^{-4}$ , unpaired t test with Holm-Sidak correction). (H) Left: Reconstruction of a recorded Som interneuron. Scale bar: 100  $\mu$ m. Right: tdTomato expression in EC in a slice from a Som-tdTomato mouse. Inset shows a representative Som interneuron response to current injection (-150 and +250 pA). Scale bar: 100  $\mu$ m. (I) Representative recording of a Som interneuron during 5-HT application. Scale bars: 10 mV, 30 s. (L) Average RP of Som interneurons during 5-HT (red) and ketanserin + 5-HT (blue) application, orange bar represents 5-HT.

reduced spiking activity of putative excitatory cells (Figure 3-figure supplement 3D). Selective activation of 5-HT<sub>2</sub>R by  $\alpha$ -methyl-5-HT could also replicate SO suppression (Figure 3-figure supplement 3C, F). Together, these results point to the importance of 5-HT<sub>2A</sub>R in the suppression of SO.


5-HT<sub>2A</sub>R activation causes an increase in intracellular calcium and consequent depolarization of the resting potential (RP) (Nichols and Nichols, 2008). Accordingly, after 5-HT application, we found that a small group of neurons was depolarized (n= 6/48, 12,5%) (Figure 3–figure supplement 4). Using a soft clustering approach with six electrophysiological parameters (see “Materials and Methods”) we divided the recorded cells in 3 groups: Excitatory (Exc), fast-spiking (FS) and low-threshold spiking (LTS) (Figure 3E, Figure 3–figure supplement 5). Strikingly, the cells excited by 5-HT belonged exclusively to the LTS group (Figure 3G, Figure 3–figure supplement 4).

A substantial part of LTS neurons expresses Som (Tremblay et al., 2016, Gibson et al., 1999), therefore we performed targeted patch-clamp recordings using a mouse line expressing tdTomato specifically in Som-expressing interneurons (Figure 3H). Som interneurons depolarized upon 5-HT application (n=19,  $\Delta$ RP:  $7.5 \pm 1.23$  mV) (Figure 3I-L) and in some cases spiked while SO were suppressed (n= 8/17, 47.05%, mean  $\text{spiking rate} = 3.03 \pm 0.39$  spikes/s). This effect was blocked by ketanserin (n = 22) (Figure 3L). We confirmed the presence of 5-HT<sub>2A</sub>R in Som interneurons using immunohistochemistry in mice expressing EGFP under the 5-HT<sub>2A</sub>R promoter. We found that  $11.8 \pm 2.9$  % of the 5-HT<sub>2A</sub>R positive cells in EC colocalized with Som (n = 7 mice) (Figure 3–figure supplement 6). These results suggest that Som interneurons might convey synaptic inhibition involved in the suppression of SO.

### **Som interneurons mediate the suppression of SO by 5-HT**

To evaluate the contribution of Som interneurons to the 5-HT-mediated silencing of SO we used an opto- and pharmacogenetic approach. First, we transgenically expressed channelrhodopsin-2 (ChR2) in Som interneurons (Figure 4A). Light-stimulation of ChR2-expressing Som interneurons in vitro suppressed SO consistently (Figure 4D-F). Expectedly, up-states associated spiking was also diminished (Figure 4C, E, F). At the end of the light stimulation spontaneous up-states immediately reoccurred (Figure 4G-H), in line with a critical role of Som interneurons in the modulation of SO (Fanselow et al., 2008, Funk et al., 2017, Niethard et al., 2018). While this experiment establishes the ability of Som interneurons to suppress SO, it does not causally link Som interneuron activation to the suppression of SO induced by 5-HT. Therefore, we generated a transgenic mouse line carrying a Cre-conditional expression cassette of the pharmacogenetic silencer hM4Di (Figure 4–figure supplement 1) (Armbruster et al., 2007). Homozygous Cre-conditional hM4Di transgenic mice and Som-Cre mice were bred to obtain heterozygous Som-Cre/hM4Di offspring, which allow specific inhibition of Som interneuron activity using Clozapine-N-Oxide (CNO). Following application of 5-HT we






**Figure 4| Som interneurons activation suppresses SO.** (A) Experimental protocol: Som interneurons expressing ChR2 are activated by light during intracellular recording of layer 3 neurons in EC. (B) Representative recordings from a L3 neuron during Som interneuron activation. Scale bars: 10 mV, 0.5 s. (C) Spikes raster (top) and density plot (bottom) during light stimulation. (D) Up-state raster (top) and density plot (bottom) during light stimulation. (E) Left: spike frequency during baseline light stimulation ( $n=14$ ;  $p < 0.001$ , Wilcoxon signed rank test). Right: Up-state incidence during baseline and light stimulation ( $n=14$ ;  $p < 0.001$ , Wilcoxon signed rank test). Patches represent 95% confidence interval, lines represent standard deviation. (F) Left: spike probability polar plot during Som interneurons light activation. Right: up-state probability polar plot during Som interneurons light activation. Note the absence of both spiking activity and up-states during Som interneurons activation.

observed a strong reduction of up-state incidence in the LFP, which was partially restored by subsequent application of CNO (Figure 5 A-B). Activation of 5-HT<sub>1A</sub>R on excitatory cells and the resulting decreased network excitation drive might account for the remaining suppression effect of 5-HT. CNO did not show any significant effect in both wildtype littermates and

hM4Di-PV mice (Figure 5-figure supplement 1), indicative of the specific role played by Som interneurons. In summary, while activation of Som interneurons either via 5-HT or directly by ChR2 suppresses SO, the pharmacogenetic inactivation of Som interneurons weakens the effect of 5-HT on SO.



**Figure 5| Som interneurons mediate the effect of 5-HT on SO.** (A) Up-state raster plot during subsequent 5-HT and CNO application. Orange box represents 5-HT, purple boxes represent CNO. Note the appearance of up-states after CNO application. (B) Up-state incidence during 5-HT and 5-HT+CNO application ( $n=15$ ;  $p_{\text{baseline vs 5-HT}} < 10^{-4}$ ,  $p_{\text{baseline vs CNO}} = 0.0482$ ,  $p_{\text{5-HT vs CNO}} = 0.0405$ , Kruskal-Wallis test). Patches represent 95% confidence intervals, lines represent standard deviation.

## Discussion

In this study we show that 5-HT suppresses default cortical network oscillations and, using an opto- and pharmacogenetic approach, we demonstrate that Som interneurons, activated by 5-HT<sub>2A</sub>R, mediate this suppression in mEC.

Organization of cortical activity is brain state-dependent, ranging continuously from “synchronized” to “desynchronized” states (Harris and Thiele, 2011). SO is on one end of this continuum, representing the prototypical synchronized state. Our results, in line with previous studies (Puig et al., 2010, Grandjean et al., 2019, Oikonomou et al., 2019), show that 5-HT can suppress synchronized cortical activity; in addition, we identify Som interneurons as necessary for this desynchronization. A parsimonious explanation that links the activation of interneurons and desynchronization relies on tracking of shared input between inhibitory and excitatory populations (Sippy and Yuste, 2013, Renart et al., 2010, Stringer et al., 2016): increased

inhibition, as shown both in computational model and experimental data, can override the effect of shared input causing net decorrelation. Som interneurons, in particular, are known to be sufficient to cause desynchronization in V1 (Chen et al., 2015). While it is well known that Som interneurons are potently excited by acetylcholine (Chen et al., 2015, Obermayer et al., 2018, Fanselow et al., 2008), our work identifies them as a novel target of 5-HT regulation via 5-HT<sub>2A</sub>R. The excitation of Som Interneurons by 5-HT is likely to contribute to the net inhibitory effect of 5-HT release in many cortical areas (Grandjean et al., 2019, Seillier et al., 2017, Azimi et al., 2020), and could explain why the inhibition strength is linearly correlated to 5-HT<sub>2A</sub>R expression (Grandjean et al., 2019). Giving further support to this idea, Som interneurons in motor and somatosensory areas show increased cFos levels following 5-HT<sub>2A</sub>R activation (Martin and Nichols, 2016). Previous works have reported direct 5-HT<sub>2A</sub>R dependent inhibition in prefrontal cortex (PFC) (Abi-Saab et al., 1999, Ashby et al., 1990, Athilingam et al., 2017), piriform cortex (Marek and Aghajanian, 1994, Sheldon and Aghajanian, 1990), cingulate cortex (Zhou and Hablitz, 1999), cochlear nucleus (Tang and Trussell, 2017), olfactory bulb (Petzold et al., 2009, Hardy et al., 2005), visual cortex (Michaël et al., 2019, Azimi et al., 2020) and hippocampus (Wyskiel and Andrade, 2016). However, none of these studies identified interneurons using molecular markers and we do not exclude that different interneuron classes in other cortical areas might mediate the inhibitory downstream effects of 5-HT<sub>2A</sub>R. For example, in PFC a subgroup of PV interneurons has been reported to be activated by this receptor (Athilingam et al., 2017, Puig et al., 2010).

5-HT modulation is also involved in gain regulation. In olfactory cortex, 5-HT has a selective subtractive effect on stimulus evoked firing (Lottem et al., 2016), and a recent work has shown in visual cortex that the reduced gain of evoked responses is dependent on 5-HT<sub>2A</sub>R activation (Azimi et al., 2020). Intriguingly, Som interneurons have been shown to regulate subtractive inhibition (Sturgill and Isaacson, 2015, Wilson et al., 2012).

Beside its involvement in various physiological brain processes, 5-HT is also associated with the etiology of various psychiatric disorders and the same applies for Som interneurons (Pantazopoulos et al., 2017, Lin and Sibille, 2015). 5-HT is also linked to the psychological effect of many psychotropic drugs. Most interestingly, 5-HT<sub>2A</sub>R activation is essential for the psychological effects induced by various psychedelics (Nichols, 2016) and, in the case of MDMA, has been linked to perceptual and emotional alterations (Liechti et al., 2000, Kuypers et al., 2018). Broadband reduction in oscillatory power, triggered by 5-HT<sub>2A</sub>R, seems to be linked to the subjective effect of serotonergic drugs (Carhart-Harris et al., 2016, Carhart-Harris and Friston, 2019) and it has been consistently observed in humans and rodents following

administration of MDMA (Frei et al., 2001, Lansbergen et al., 2011) or various other 5-HT<sub>2A</sub>R agonists (Kometer et al., 2015, Muthukumaraswamy et al., 2013, Carhart-Harris et al., 2016, Wood et al., 2012). The link between 5-HT<sub>2A</sub>R and perception is further supported by the fact that a number of routinely used antipsychotic drugs are potent 5-HT<sub>2A</sub>R antagonists (Marek et al., 2003, Meltzer, 1999). While the most recent attempts to explain the psychological effects of 5-HT<sub>2A</sub>R activation focus on the increased spiking of cortical pyramidal neurons in the deep layers (Carhart-Harris and Friston, 2019, Nichols, 2016), our study suggests that Som interneurons may also play a role. Som interneurons, in contrast to PV interneurons, biasedly form synapses on the dendrites of their target cell (Tremblay et al., 2016). A wealth of evidence suggests that active dendritic processing in cortical pyramidal neurons has a critical influence on sensory perception (Takahashi et al., 2016, Murayama et al., 2009, Smith et al., 2013, Ranganathan et al., 2018) and, in accordance to their unique anatomical properties, Som interneurons strongly influence dendritic computations and directly modulate perceptual thresholds (Takahashi et al., 2016). We propose that the novel link between 5-HT<sub>2A</sub>R and Som interneurons might help elucidate the mechanism underlying a host of psychiatric disorders and contribute to our understanding of how serotonergic drugs exert their psychological effects.

## 299 **Materials and Methods**

300 All experiments were conducted according to regulations of the Landesamt für Gesundheit  
301 und Soziales (Berlin [T 0100/03], Berlin [G0298/18]) and the European legislation (European  
302 Directive 2010/63/EU).

### 303 **Animals**

304 Data for the *in vivo* part of the study were collected from C57BL6 mice (aged 6 to 10 weeks).  
305 Data for the *in vitro* part were collected from C57BL6 (P10-P17), Som-tdtomato (P10-P30),  
306 Sst-Chr2-EYFP (P10-P16), hM4Di-Som (P10-P15), hM4Di-Som (+/-) (P10-P15) and hM4Di-  
307 PV (P10-P15) mice. Immunostainings to localize 5-HT<sub>2A</sub>R were performed on 5-HT<sub>2A</sub>R-EGFP  
308 mice (P20-P90) and Immunostainings to localize 5-HT fibers (Fig.1 c) were performed on an  
309 ePet-YFP mouse (P35). The animals were housed in a 12:12 hours light-dark cycle in singularly  
310 ventilated cages with *ad libitum* access to food and water. SO *in vitro* recordings were  
311 performed on P12-P16 mice.

### 312 **Drugs**

313 Urethane (U2500, Sigma), fenfluramine ((+)-Fenfluramine hydrochloride, F112, Sigma), 5-HT  
314 (Serotonin creatinine sulfate monohydrate, H7752, Sigma), WAY-100635 (W108, Sigma), α-  
315 Methylserotonin (α-Methylserotonin maleate salt, M110, Sigma) MDMA ((±)3,4-  
316 methylenedioxymethamphetamine, 64057-70-1, Sigma), CNO (Clozapine N-oxide  
317 dihydrochloride, 6329, Tocris) were dissolved in water for *in vitro* application and in 0.9%  
318 normal saline for *in vivo* application. Ketanserin (Ketanserin (+)-tartrate salt, S006, Sigma) was  
319 dissolved in Dimethyl sulfoxide (DMSO).

### 320 **Surgery and *in vivo* recording**

321 Mice were briefly anaesthetized with isofluorane (2%) and then injected intraperitoneally with  
322 urethane (1,2 g/kg, Sigma Aldrich, Munich, Germany). The level of anesthesia was maintained  
323 so that hindlimb pinching produced no reflex movement and supplemental doses of urethane  
324 (0.2 g/kg) were delivered as needed. Upon cessation of reflexes the animals were mounted  
325 on a stereotaxic frame (Kopf Instruments, Tujunga, California), and body temperature was  
326 maintained at 38°C. The scalp was removed, and the skull was cleaned with saline solution.  
327 A craniotomy was performed at +3 mm ML, -3 mm AP, +3.25 mm DV.



Extracellular recordings from EC were performed using a Cambridge Neurotech 64-channels (n = 15) or 32-channels (n = 3) silicon probe. The recording electrode was painted with the fluorescent dye Dil (Thermo Fisher Scientific, Schwerte, Germany) and then slowly lowered into the craniotomy using micromanipulators (Luigs&Neumann, Ratingen, Germany) at a 25° angle AP (toward the posterior side of the brain). The exposed brain was kept moist using saline solution. A ground wire connected to the amplifier was placed in the saline solution covering the skull to eliminate noise. Brain signals were recorded using a RHD2000 data acquisition system (Intan Technologies, Los Angeles, California) and sampled at 20kHz. Recording quality was inspected on-line using the open-source RHD2000 Interface Software. Recordings began after a 10-minute waiting period in which clear Up-states could consistently be seen at a regular frequency.

### ***In vivo analysis***

We selected the channel to use for up-state detection based on the standard deviation (STD) of the trace during baseline (first 5 minutes of recording), the channel with the highest STD was selected as larger voltage deflection increases detection algorithm accuracy. Given the highly synchronous nature of SO (Supplementary Fig. 3) the spatial location of the channel selected was not considered. Up-states were detected comparing threshold crossing points in two signals: the delta-band filtered signal (0.5-4 Hz) and the population spike activity. Candidate up-states were identified in the delta-band filtered signal using two dynamic thresholds ‘a’ and ‘b’:

$$a = m + \frac{\sigma}{1.5}$$

$$b = m + \frac{\sigma}{0.8}$$

Where  $\sigma$  is the standard deviation of the signal during the first five minutes of recording (baseline) and  $m$  is the centered moving median calculated using 60 s windows (Matlab function *movmedian*). The median was used instead of the mean to account for non-stationaries in the data. A candidate up-state was identified at first using the threshold crossings of the signal compared to ‘a’: candidates shorter than 200 ms were deleted and candidates happening in a window of 300 ms were joined together. Subsequently the threshold ‘b’ was used to separate up-states occurring in close proximity: if the signal within one candidate crossed the threshold ‘b’ in more than one point then the candidate up-state was split in two at the midpoint between the two threshold crossings. Candidate up-states

were finally confirmed if the population spike activity (calculated in 100 ms windows) within the candidate crossed a threshold of  $1 \sigma$  (calculated during the baseline).

## Units detection and classification

Spike detection was performed offline using the template-based algorithm Kilosort2 (<https://github.com/MouseLand/Kilosort2>), with the following parameters:

- ops.fshigh = 300
- ops.fsslow = 8000
- ops.minfr\_goodchannels = 0
- ops.Th = [8 4]
- ops.lam = 10
- ops.AUCsplit = 0.9
- ops.minFR = 1/1000
- ops.momentum = [20 400]
- ops.sigmaMask = 30
- ops.ThPre = 8
- ops.spkTh = -6
- ops.nfilt\_factor = 8
- ops.loc\_range = [3 1]
- ops.criterionNoiseChannel = 0.2
- ops.whiteningrange = 32
- ops.ntbuff = 64

Manual curation of the results was performed using Phy (<https://github.com/cortex-lab/phy>). Each Isolated unit satisfied the following two criteria: Refractory period (2 ms) violations < 5%, fraction of spikes below detection threshold (as estimated by a gaussian fit to the distribution of the spike amplitudes) < 15%. Units with negative maximal waveform amplitude were further classified as putative excitatory if the latency (TP latency) was  $\geq 0.55$  ms or putative inhibitory when TP latency < 0.55 ms. The value 0.55 was chosen in accordance with previous works (Senzai et al., 2019, Antoine et al., 2019). Pharmacological classification: units were classified as ‘activated’ if their firing rate in the 25 minutes following drug injection was  $2 \sigma$  (standard deviation) above the baseline rate for at least 5 minutes. Remaining units were pulled together in the category ‘non-activated’.

## 390 **Cross-correlogram analysis**

391 Cross-correlogram based connectivity analysis was performed for every unit to identify  
 392 inhibitory connections. Units with a spiking rate smaller than 0.3 spikes/s were discarded from  
 393 the analysis. We used total spiking probability edges (TPSE) algorithm  
 394 (<https://github.com/biomemsLAB/TSPE>) (De Blasi et al., 2019) to identify in a computationally  
 395 efficient manner putative inhibitory connections between units and all clusters recorded. The  
 396 parameters used were:

397

- 398       ▪  $d = 0$ ,
- 399       ▪  $neg\_wins = [2, 3, 4, 5, 6, 7, 8]$ ,
- 400       ▪  $co\_wins = 0$ ,
- 401       ▪  $pos\_wins = [2, 3, 4, 5, 6]$ ,
- 402       ▪  $FLAG\_NORM = 1$ .

403

404 The connectivity vectors of each unit resulting from TSPE were sorted by inhibition strength.  
 405 Top 20 connections were further analyzed using custom Matlab code. A connection was  
 406 classified as inhibitory if the cross correlogram values ( $x$ ) were smaller than the mean of  $x$  by  
 407 more than one standard deviation ( $x < \text{mean}(x) - \text{std}(x)$ ) in at least 4 consecutive bins (bin size  
 408 = 1 ms) in a window 4 to 9 ms after the center of the cross-correlogram.

## 409 **Slice preparation**

410 We prepared acute near horizontal slices ( $\sim 15^\circ$  off the horizontal plane) of the medial  
 411 entorhinal cortex (mEC) from C57Bl6/n mice. Animals were decapitated following isoflurane  
 412 anesthesia. The brains were quickly removed and placed in ice-cold ( $\sim 4^\circ \text{C}$ ) ACSF (pH 7.4)  
 413 containing (in mM) 85 NaCl, 25  $\text{NaHCO}_3$ , 75 Sucrose, 10 Glucose, 2.5 KCl, 1.25  $\text{NaH}_2\text{PO}_4$ ,  
 414 3.5  $\text{MgSO}_4$ , 0.5  $\text{CaCl}_2$ , and aerated with 95%  $\text{O}_2$ , 5%  $\text{CO}_2$ . Tissue blocks containing the brain  
 415 region of interest were mounted on a vibratome (Leica VT 1200, Leica Microsystems), cut at  
 416 400  $\mu\text{m}$  thickness, and incubated at  $35^\circ \text{C}$  for 30 min. The slices were then transferred to  
 417 ACSF containing (in mM) 85 NaCl, 25  $\text{NaHCO}_3$ , 75 Sucrose, 10 Glucose, 2.5 KCl, 1.25  
 418  $\text{NaH}_2\text{PO}_4$ , 3.5  $\text{MgSO}_4$ , 0.5  $\text{CaCl}_2$ . The slices were stored at room temperature in a  
 419 submerged chamber for 1-5 hr before being transferred to the recording chamber.

## 420 ***In vitro* recording**

In order to perform whole-cell recordings slices were transferred to a submersion style recording chamber located on the stage of an upright, fixed-stage microscope (BX51WI, Olympus) equipped with a water immersion objective ( $\times 60$ , Olympus) and a near-infrared charge-coupled device (CCD) camera. The slices were perfused with ACSF ( $\sim 35^\circ\text{C}$  bubbled with 95 %  $\text{O}_2$ -5 %  $\text{CO}_2$ ) at 3-5 ml/ min to maintain neuronal health throughout the slice. The ACSF had the same composition as the incubation solution except for the concentrations of calcium and magnesium, which were reduced to 1.2 and 1.0 mM, respectively. Recording electrodes with impedance of 3-5  $\text{M}\Omega$  were pulled from borosilicate glass capillaries (Harvard Apparatus, Kent, UK; 1.5 mm OD) using a micropipette electrode puller (DMZ Universal Puller). The intracellular solution contained the following (in mM): 135 K-gluconate, 6 KCl, 2  $\text{MgCl}_2$ , 0.2 EGTA, 5  $\text{Na}_2$ - phosphocreatine, 2  $\text{Na}_2$ -ATP, 0.5  $\text{Na}_2$ -GTP, 10 HEPES buffer, and 0.2% biocytin. The pH was adjusted to 7.2 with KOH. Recordings were performed using Multiclamp 700A/B amplifiers (Molecular Devices, San Jose, California). The seal resistance was  $>1\text{ G}\Omega$ . Capacitance compensation was maximal and bridge balance adjusted. Access resistance was constantly monitored. Signals were filtered at 6 kHz, sampled at 20 kHz, and digitized using the Digidata 1550 and pClamp 10 (Molecular Devices, San Jose, California). Activation light was delivered by a 460 nm laser (DPSS lasers, Santa Clara, California) using a 460–480 nm bandpass excitation filter. Stimulation consisted of 500 ms pulses at 1 Hz. Stimulation experiments were performed using a bipolar micro-electrode (glass pipette filled with ACSF solution, wrapped by a fine grounding wire) connected to an isolated voltage stimulator (ISO-Flex, A.M.P.I., Israel). A 4x objective (Olympus) was used to visually guide the stimulating electrode into the mEC. Stimulation power was adjusted to achieve consistent up-state generation during baseline ( $> 95\%$ ). Each stimulus had a duration of 50  $\mu\text{s}$ , inter-stimuli interval was 8-10 seconds.

## **In vitro analysis**

*In vitro* up-states were detected in Matlab using an algorithm similar to the one described in the *in vivo analysis* method section. We used a coincident detection in two signals. In multicellular recordings we used the membrane potential of 2 cells, in single cell recording we used membrane potential and the envelope of the gamma filtered trace (50-250 Hz), as up-states are characterized by an increase in gamma activity (Neske, 2015). Baseline condition was calculated using the last 120 s before drug application, post-drug application condition was calculated using the last 120 s of recording after drug application (Total recording duration: 600 s).

Excitatory (Exc), fast spiking (FS) and low-threshold spiking (LTS) neurons were classified using Gaussian mixture models (GMM) with a soft clustering approach in Matlab. Input resistance ( $R_{in}$ ),  $\Delta$ after-hyperpolarization ( $\Delta AHP$ ), sag, rheobase, spike width and resting potential (RP) were extracted from each neuron and used in the classification. The first two components of the principal component analysis (PCA) were used to fit the data to a Gaussian mixture model distribution. Initial values were set according to the k-means algorithm with centroid positioned at x and y position: 5, 0; -15, -15; -15, 10. This centroid were placed according to the loadings of the PCA to identify 3 clusters with the following main features:

- Cluster 1 (putative Exc): high spike width, low AHP, low rheobase.
- Cluster 2 (putative FS): low spike width, low SAG, high rheobase, low  $R_{in}$ .
- Cluster 3 (putative LTS): low spike width, high SAG, high AHP, high  $R_{in}$ .

Covariance matrices were diagonal and not shared. Neurons with a posterior probability of belonging to any of the three clusters < 90% were discarded from further analysis (1/49). While the majority of Som-interneurons display LTS features, a minority (~10%) belongs to the FS group (Urban-Ciecko et al., 2015). To distinguish FS and LTS interneurons in the SOM-Td Tomato mice we employed the GMM with posterior probability threshold of 90%.

## Inter-area connectivity analysis

Projection data was downloaded from the Allen Mouse Brain Connectivity Atlas via the provided API (application programming interface) using freely available code (<https://github.com/SainsburyWellcomeCentre/AllenBrainAPI>). Different connectivity metrics are provided for each experiment:

- Normalized projection volume =  $\frac{\text{Projection volume}}{\text{Total volume of signal in injection site}}$
- Projection density =  $\frac{\text{Number of pixels identified as projecting in the structure}}{\text{Number of valid pixels in the structure}}$
- Projection intensity =  $\frac{\text{Sum of intensity values in projecting pixels in the structure}}{\text{Number of pixels identified as projecting in the structure}}$
- Projection energy =  $\frac{\text{Projection density}}{\text{projection intensity}}$

We chose to use projection energy as it directly relates signal strength (pixel intensity) to the size of a give structure (total number of pixels in the structure), in this case a widely spread



weak signal and a narrow strong signal may both have similar projection energies. Projection energy was normalized across different experiments dividing by the injection volume. Projection signal in injection area was excluded. More information about the record properties can be found on the Allen SDK (software development kit) website <https://alleninstitute.github.io/AllenSDK/unionizes.html>. Each annotation was assigned a new additional structure ID to enable the calculation of average projection energy per area. Entorhinal cortex (EC) output was calculated combining the results of experiments 114472145 (injection site: lateral EC) and 113226232 (injection site: medial EC). Connectivity analysis was performed using custom Matlab (2018a) code, the code is available on Github (<https://github.com/RobertoDF/BRIO>).

### Generation of Cre-conditional hM4Di mice

We produced a transgenic mouse line carrying a Cre-conditional hM4Di expression cassette in the Rosa26 locus. The transgene construct was inserted by recombination-mediated cassette exchange (RMCE). RMCE relies on recombination events between attB and attP recognition sites of the RMCE plasmid and genetically modified acceptor embryonic stem (ES) cells, mediated by the integrase of phage phiC31 (Hitz et al., 2007). The RMCE construct is thereby shuttled into the Rosa26 locus of the ES cells, along with a Neomycin resistance cassette (fig. S12A). The acceptor cell line IDG3.2-R26.10-3 (I3) was kindly provided by Ralf Kühn (GSF National Research Centre for Environment and Health, Institute of Developmental Genetics, Neuherberg, Germany).

We subcloned a Cre-conditional FLEX (flip-excision) cassette (Schnutgen et al., 2003) into pRMCE, and inserted a strong CAG promoter (CMV immediate early enhancer/modified chicken  $\beta$ -actin promoter, from Addgene Plasmid #1378) in front of the FLEX-cassette to create pRMCE-CAG-Flex. The coding sequence of hM4Di-mKateT was inserted into the FLEX cassette in reverse orientation to the promoter (fig. S12A). Finally, a rabbit globulin polyA cassette including stop codons in every reading frame was placed downstream of the FLEX cassette, in the same direction as hM4Di, in order to prevent unintended transcriptional read-through from potential endogenous promoters. The construct was completely sequenced before ES cell electroporation.

Electroporation of the RMCE construct together with a plasmid encoding C31int was performed by the transgene facility of the 'Research Institute for Experimental Medicine' (FEM, Charité, Berlin) according to published protocols (Hitz et al., 2009, Hitz et al., 2007). Recombinant clones were selected by incubation with 140  $\mu$ g/ml G418 for at least 7 days. To activate hM4Di

expression by recombination of the FLEX switch, selected clones were further transfected transiently with pCAG-Cre-EGFP using Roti-Fect (Carl Roth, Karlsruhe, Germany). G418-resistant clones were analyzed by PCR for successful integration and recombination of the construct (fig. S12B), using the following primer:

GT001	PGK3'-fw:	CACGCTTCAAAGCGCACGTCTG;
GT002	Neo5'-rev:	GTTGTGCCCAGTCATAGCCGAATAG;
GT005	PolyA-fw:	TTCCTCCTCTCCTGACTACTCC;
GT006	Rosa3'-rev:	TAAGCCTGCCCAGAAGACTC;
GT013 hM4Di3'rec-rev:		CAGATACTGCGACCTCCCTA

After verification of correct integration and functional FLEX-switch recombination, we generated chimeras by blastocyst injection of I3 ES cells. Heterozygous offsprings were mated with a Flpe deleter mouse line in order to remove the neomycin resistance cassette by Flp-mediated recombination.

Mice homozygous for the Rosa-CAG-FLEX-hM4Di-mKateT allele are viable and fertile and show no obvious phenotype. Importantly, application of CNO to these mice does not induce any behavioral effects. Homozygous Cre-conditional hM4Di transgenic mice and Som-Cre mice (Taniguchi et al., 2011) were maintained on a C57BL/6n genetic background and were bred to obtain heterozygous Som-Cre / hM4Di offsprings.

## Histological analysis

For the *post-mortem* electrode tracks reconstructions of the *in vivo* recordings, mice were not perfused, brain were extracted from the skull, post-fixed in 4% PFA overnight at 4°C and afterwards cut with a vibratome (Leica Microsystems, Wetzlar Germany) in 100 µm thick sequential sagittal slices. Images were taken using a 1.25x objective and stitched together using the microscope software (BX61, Olympus), afterwards we used AllenCCF code (<https://github.com/cortex-lab/allenCCF>) to identify electrode shanks location (Shamash et al., 2018).

For the anatomical reconstructions of recorded cells *in vitro* brain slices were fixed with 4% paraformaldehyde in 0.1 M phosphate buffer (PB) for at least 24 hours at 4°C. After being washed three times in 0.1 M PBS, slices were then incubated in PBS containing 1% Triton X-100 and 5% normal goat serum for 4 hr at room temperature (RT). To visualize biocytin-filled cells we used Streptavidin Alexa 488 conjugate (1:500, Invitrogen), WFS1 (1:1000, Rabbit, Proteintech, IL, USA) was used in a subset of analysis to visualize the L2/L3 border, Som (1:1000, Rat, Bachem, Switzerland) was used in the 5-HT<sub>2A</sub>R localization analysis. Slices were

incubated with primary antibodies for 48 hours at RT. After rinsing two times in PBS, sections were incubated in the PBS solution containing 0.5% Triton X-100, Alexa fluor 488, Alexa fluor 555 and Alexa fluor 647 (Invitrogen Corporation, Carlsbad, CA) according to the number of antibodies used. Slices were mounted in Fluoroshield (Sigma-Aldrich) under coverslips 2-3 hr after incubation with the secondary antibodies and stored at 4 °C. Labeled cells were visualized using 20x or 40x objectives on a confocal microscope system (SP8, Leica). For the 5-HT<sub>2A</sub>R localization analysis images of the whole EC were acquired and stitched together using the auto stitching method, with smoothing set to off. Z stacks were acquired every 30 μM. The Image stacks obtained were registered and combined in Fiji (<http://fiji.sc/wiki/index.php/Fiji>) to form a montage of the sections. Cell counting was executed using Fiji multi-point tool. X-Y-Z coordinates of each 5-HT<sub>2A</sub>R-EGFP positive cell were exported to Matlab and subsequently, using custom written code in Matlab, we semi-automatically inspected each cell for colocalization between EGFP(5-HT<sub>2A</sub>R) and Som.

## Statistical Analysis

All datasets were tested to determine normality of the distribution either using D'Agostino-Pearson omnibus normality test or Shapiro-Wilk normality test. Student's t-test and one-way ANOVA were used for testing mean differences in normally distributed data. Wilcoxon matched-pairs signed rank test and Kruskal-Wallis were used for non-normally distributed datasets. Dunn-Sidak multiple comparison test was used to compare datasets with 3 or more groups. Kolmogorov-Smirnov test was used to compare cumulative distributions. Statistical analysis was performed using Prism (6.01) and Matlab (2019a). All data are expressed as mean ± SEM Asterisks in figures represents p-values smaller than 0.05 unless stated otherwise in the legend.

## Data and code availability


The code generated during this study is available from the corresponding author upon reasonable request.

**Acknowledgments:** We thank A. Schönherr, S. Rieckmann, K. Cziesselzky, A. Fortströer, A.R. Sammons, M. Brecht, M. E. Larkum.

**Author contributions:** Conceptualization: R.D.F. and D.S.. Methodology: J.J.T., P.B., R.D.F. and B.R.. Investigation: R.D.F, A.S., C.C. and P.B. Software and formal analysis: R.D.F..


579 Resources: P.B. and C.H.. Supervision: D.S.. Project administration: R.D.F., D.S.. Funding  
580 acquisition: D.S.. Original draft preparation: R.D.F. and D.S. Review and editing: all authors.  
581

582 **Supplementary Figures**




583 **Figure 1-figure supplement 1. Regional output connectivity of EC.**  
584 (A) Projection energy of all identified EC outputs color coded according to Allen institute  
585 standard: green = cerebral cortex, blue= cerebral nuclei, pink = midbrain, red =  
586 interbrain/hindbrain and yellow = cerebellum. (B) Same data as (A) consolidated in higher level  
587 regions.  
588






**Figure 1-figure supplement 2. *In vivo* up-state metrics.**

**(A)** Average up-state voltage deflection, grey patch represents 1 standard deviation ( $n_{\text{detected up-states}} = 2655$ ,  $n_{\text{animals}} = 18$ ). For each recording the channel with the biggest voltage deflection was selected, see “Methods”. For experiments with drug application (either MDMA or Fen) only baseline up-states were taken in account. **(B)** Violin plots of duration (mean:  $0.87 \pm 0.008$  s), peak 1 amplitude (mean:  $218.59 \pm 1.83$  μV), peak 2 amplitude (mean:  $108.27 \pm 0.97$  μV) and area (mean:  $160.88 \pm 1.31$  μV·s) of each detected up-state. **(C)** Scatter plots showing relationships between metrics used in (B). Bold black number in each plot represent the correlation coefficient ( $p < 0.001$ ).



599 **Figure 1-figure supplement 3. *In vivo* up-state spatial features.**

600 **(A)** Microelectrode implant location and microelectrode features. 64 channels ( $n_{\text{animals}} = 15$ ,  $n_{\text{shanks}} = 4$ ) and 32 channels ( $n_{\text{animals}} = 3$ ,  $n_{\text{shanks}} = 2$ ) microelectrodes were used in this study,  
601 analysis shown in this figure excludes data recorded with 32 channels probe due to the  
602 different spatial configuration of the channels. **(B)** Average up-state voltage deflection for each  
603 channel of the microelectrode. For experiments with drug application (either MDMA or Fen)  
604 only baseline up-states were taken in account. **(C)** Left: Average up-state voltage deflection  
605 grouped by shank. Right: Average up-state voltage deflection grouped by depths (right).  
606 Insets show the normalized correlation between averages in the two different groups. **(D)**  
607 Scatter plots showing significant correlation between shank number and peak 1 (left) and  
608 between shank number and peak 1 (right). Bold black number in each plot represent the  
609 correlation coefficient ( $p < 0.001$ ). **(E)** Scatter plots showing significant correlation between  
610 recording channel depth and peak 1 (left) and between recording channel depth and peak 1  
611 (right). Bold black number in each plot represent the correlation coefficient ( $p < 0.001$ ).  
612




**Figure 2-figure supplement 1. Cross-correlogram (CCG) based connectivity analysis.**

**(A)** Units are plotted according to TP latencies and repolarization time and color-coded according to the number of inhibitory connections detected. Units displaying a TP latency < 0.55 ms were classified as putative inhibitory interneurons ('Putative int'), the remaining units were classified as putative excitatory neurons ('Putative exc'). Inhibitory connections were detected using Total Spiking Probability Edges (TSPE) (See Supplementary materials). Putative interneurons had a 40.0 % chance of displaying at least one inhibitory connection in the CCGs with an average number of  $3.38 \pm 0.68$  inhibitory connections while putative excitatory cells had a 0.33 % chance of displaying inhibitory connections. **(B)** Connectivity


scheme of one putative inhibitory unit (source unit, black circle) displaying 10 inhibitory connections with surrounding clusters. Grey rhombi represent recording channels on the probe with the tip of the shanks pointing north. Each colored circle represents the location of an inhibited unit. Waveforms of the inhibited units are plotted nearby the location using the same color. Inset shows the location of the source unit on the probe. **(C)** CCGs of the connections displayed in (B) using the same color code. Solid lines represent mean, dashed lines represent 1 standard deviation.






**Figure 2-figure supplement 2. TP latency density distributions.**

**(A)** Dashed lines represent kernel density estimations of probability density functions of the TP latencies of putative inhibitory (blue), putative excitatory (black) and 'activated' units. Solid lines represent gaussian fitting curves for each group. Peak inhibitory gaussian: 0.31 ms, peak excitatory gaussian: 0.81 ms and peak 'activated' gaussian: 0.56 ms. **(B)** Goodness of fit metrics for each gaussian fit. Sse = Sum of squares due to error, rsquare = R-squared (coefficient of determination), dfe = Degrees of freedom in the error, adjrsquare = Degree-of-freedom adjusted coefficient of determination.




**Figure 3-figure supplement 1. Effect of fenfluramine on SO.**

**(A)** Histogram of UDS incidence before and after fenfluramine application ( $n=6$ , baseline:  $1.04 \pm 0.15$  Up-states/10s, fenfluramine:  $0.01 \pm 0.01$  Up-states/10s). **(B)** Up-state raster plot during fenfluramine application. **(C)** Change in resting potential (RP) after fenfluramine application ( $n=13$ ,  $\Delta RP = -0.70 \pm 1.17$  mV).




**Figure 3-figure supplement 2. 5-HT suppresses evoked up-states.**

**(A)** Experimental protocol: recording and stimulation electrode were placed in mEC layer 3, stimulation electrode was located towards the lateral side of the slice. **(B)** Effect of electrical stimulation before (black) and after 5-HT application (orange). 5-HT consistently suppresses spiking, increasing the stimulation power up to 10 times ( $n = 40/80$  in 4 neurons) had no rescue effect. Top: voltage responses to electrical stimulation of a representative neuron. Middle: summary spike raster plot before and after 5-HT application. Bottom: spike rate line histogram **(C)** Scatter plot showing area (top,  $n = 8$  neurons, mean<sub>control</sub> =  $16.22 \pm 0.80$ , , mean<sub>5-HT</sub> =  $1.24 \pm 0.97$ ,  $p < 10^{-4}$ , Wilcoxon matched-pairs signed rank test) and duration (bottom,  $n = 8$  neurons, mean<sub>control</sub> =  $1.92 \pm 0.07$ , , mean<sub>5-HT</sub> =  $0.24 \pm 0.01$ , ,  $p < 10^{-4}$ , Wilcoxon matched-pairs signed rank test) of evoked up-states before (black) and after 5-HT application (orange). **(D)** Representative voltage responses to 1 second 4 Hz stimulation following wash-in (left) and wash-out (right) of 5-HT. 5-HT prevents spiking from input summation.



**Figure 3-figure supplement 3. 5-HT<sub>2A</sub>Rs are involved in 5-HT mediated SO suppression.** (A) Top: Up-state raster plot during application of WAY 100635 (5-HT<sub>1A</sub> antagonist) + 5-HT. Bottom: Change in RP in putative excitatory cells after application of WAY 100635 (5-HT<sub>1A</sub> antagonist) + 5-HT (n = 25 cells). (B) Top: Up-state raster plot during application of ketanserin (5-HT<sub>2A</sub> antagonist) + 5-HT. Bottom: Change in RP in putative excitatory cells after application of ketanserin (5-HT<sub>2A</sub> antagonist) + 5-HT (n = 21 cells). (C) Top: Up-state raster plot during application of α-methyl-5-HT (5-HT<sub>2</sub> agonist). Bottom: Change in RP in putative excitatory cells after application of α-methyl-5-HT (5-HT<sub>2</sub> agonist) (n = 11 cells). (D) Dot plot showing spiking rate before and after ketanserin + 5-HT (n=20, ketanserin: 0.38 ± 0.14 spikes/s, ketanserin + 5-HT: 0.15 ± 0.06 spikes/s, p= 0.011, Wilcoxon signed rank test). (E) Dot plot showing change in RP for each pharmacological condition (5-HT: -4.52 ± 0.64 mV, WAY + 5-HT: -4.52 ± 0.64 mV, ketanserin + 5-HT: -4.52 ± 0.64 mV, α-methyl-5-HT: -4.52 ± 0.64 mV).

668 HT:  $-2.09 \pm 0.47$  mV, ketanserin + 5-HT:  $-3.68 \pm 0.60$  mV and  $\alpha$ -methyl-5-HT:  $-1.67 \pm 1.13$   
669 mV;  $p = 0.0329$ , Kruskal-Wallis with Dunn's multiple comparisons test). **(F)** Dot plot showing  
670 percentage reduction of up-states incidence for each pharmacological condition (5-HT:  $95 \pm$   
671  $4$  %, WAY + 5-HT:  $100 \pm 0$  %, ketanserin + 5-HT:  $57 \pm 10.1$  % and  $\alpha$ -methyl-5-HT:  $100 \pm 0$   
672 %;  $p < 10^{-4}$ , Kruskal-Wallis with Dunn's multiple comparisons test).  
673




**Figure 3-figure supplement 4. LTS neurons are depolarized by 5-HT.**

**(A)** PCA projection plot of all the cells recorded. Cells are color coded according to group identity: excitatory (black), fast spiking (blue), low-threshold spiking (orange) and layer II stellate (grey). Empty circles represent PCA loadings. **(B)** PCA projection plot color coded according to  $\Delta \text{mV}$  after 5-HT application. Inset shows a recording from one LTS neuron during 5-HT application. Scale bars: 20 mV, 25 s. Dotted line showing -70 mV. **(C)** PCA projection plot color coded according to  $\Delta \text{spikes/s}$  after 5-HT application. **(D)** Posterior probability of being classified as Exc, FS or LTS.



**A**




**B**

	Exc	FS	LTS
Rin	277.97 ± 57.52	69.38 ± 13.20	135.77 ± 18.47
AHP	10.68 ± 2.38	3.78 ± 4.46	-0.42 ± 1.00
SAG	16.70 ± 5.03	1.17 ± 1.16	6.84 ± 2.40
RP	61.11 ± 14.40	266.67 ± 60.23	76.47 ± 22.37
Rheobase	0.71 ± 0.11	0.52 ± 0.09	1.43 ± 0.17
Spike width	-65.03 ± 3.87	-69.13 ± 8.36	-64.80 ± 2.08

**Figure 3-figure supplement 5. Excitatory, fast-spiking and LTS cells have unique sets of electrophysiological features.**


**(A)** Box plot showing the values of input resistance ( $R_{in}$ ), delta after-hyperpolarization ( $\Delta AHP$ ), SAG, RP, rheobase and spike width of excitatory (Exc, black), fast spiking (FS, blue) and low-

687 threshold spiking (LTS, green) cells ( $n_{\text{EXC}} = 33$ ,  $n_{\text{FS}} = 6$ ,  $n_{\text{LTS}} = 9$  ; asterisk means  $p < 0.05$ , double  
688 asterisk means  $p < 0.01$ ). **(B)** Table showing values plotted in (A).  
689




**Figure 3-figure supplement 6. Spatial localization of 5-HT<sub>2A</sub>R positive cells in EC.**

**(A)** 3D visualization of EC (purple). **(B)** 3D localization of all the 5-HT<sub>2A</sub>R positive cells detected in EC using same perspective as (A). **(C and D)** Co-localization of 5-HT<sub>2A</sub>R and Som, arrows point to colocalized cells (scale bar: 100 μm,  $n_{\text{animals}} = 7$ , total number of 5-HT<sub>2A</sub>R positive cells = 3570, average number of 5-HT<sub>2A</sub>R positive cells per animal =  $510 \pm 80.32$ ). **(E)** Spatial distribution of 5-HT<sub>2A</sub>R positive cells and colocalized cells along the 3 dimensions depicted in (A) (Z dimension centered on the midline).



**Figure 4-figure supplement 1. Vector construction and RMCE for the generation of a transgenic mouse line with Cre-conditional hM4Di expression.**

(A) The coding sequence of hM4Di-mKate flanked by two opposing *loxP* and *lox2272* sites was placed in reverse orientation to the CAG- promoter in the pRMCE. In the acceptor ES cells the ROSA26 allele harbours a PGK promoter driving the hygromycin selection marker, flanked by two attP sites. RMCE by C31int replaces the hygromycin resistance by the neomycin resistance of the donor vector. Location of primer binding sites in the Rosa26-hM4Di locus is indicated by green triangles. (B) Identification of successful genomic integration events and Cre-mediated inversion of the hM4Di coding sequence by PCRs. PCR 1 and PCR 2 test for correct integration of the 5' and 3' end of the construct into the ROSA26 locus. The lower band in PCR 1 results from the Neomycin resistance cassette of the feeder cells in the ES cell culture. PCR 3 tests for successful recombination of the FLEX site by Cre. A successful Cre-mediated recombination of the FLEX cassette was observed for clone 1, resulting in an 826 bp product in PCR 3. C: control cells (not electroporated), H: H<sub>2</sub>O input.



**Figure 5-figure supplement 1. CNO application in wildtype littermates and PV-hM4Di mice.**

**(A)** CNO application in wildtype littermates. Top: Experimental protocol. Orange box represents 5-HT and purple boxes represent CNO application. Bottom: Up-state incidence during 5-HT and 5-HT+CNO application, patches represent 95% confidence interval, lines represent standard deviation ( $n = 11$  cells in 4 mice, mean<sub>baseline</sub> =  $0.91 \pm 0.10$ , mean<sub>5-HT</sub> =  $0.09 \pm 0.04$ , mean<sub>CNO</sub> =  $0.01 \pm 0.01$ ,  $p_{\text{baseline vs 5-HT}} = 0.0004$ ,  $p_{\text{baseline vs CNO}} < 10^{-4}$ , Kruskal-Wallis test)

**(B)** Same as (A) but in in PV-hM4Di mice ( $n = 10$  cells in 4 mice, mean<sub>baseline</sub> =  $1.02 \pm 0.08$ , mean<sub>5-HT</sub> =  $0.04 \pm 0.03$ , mean<sub>CNO</sub> =  $0.08 \pm 0.07$ ,  $p_{\text{baseline vs 5-HT}} < 10^{-4}$ ,  $p_{\text{baseline vs CNO}} = 0.0003$ , Kruskal-Wallis test).

# References

- ABI-SAAB, W. M., BUBSER, M., ROTH, R. H. & DEUTCH, A. Y. 1999. 5-HT<sub>2</sub> receptor regulation of extracellular GABA levels in the prefrontal cortex. *Neuropsychopharmacology*, 20, 92-6.
- ANTOINE, M. W., LANGBERG, T., SCHNEPEL, P. & FELDMAN, D. E. 2019. Increased Excitation-Inhibition Ratio Stabilizes Synapse and Circuit Excitability in Four Autism Mouse Models. *Neuron*, 101, 648-661.e4.
- ARMBRUSTER, B. N., LI, X., PAUSCH, M. H., HERLITZE, S. & ROTH, B. L. 2007. Evolving the lock to fit the key to create a family of G protein-coupled receptors potentially activated by an inert ligand. *Proc Natl Acad Sci U S A*, 104, 5163-8.
- ASHBY, C. R., JR., JIANG, L. H., KASSER, R. J. & WANG, R. Y. 1990. Electrophysiological characterization of 5-hydroxytryptamine<sub>2</sub> receptors in the rat medial prefrontal cortex. *J Pharmacol Exp Ther*, 252, 171-8.
- ATHILINGAM, J. C., BEN-SHALOM, R., KEESHEN, C. M., SOHAL, V. S. & BENDER, K. J. 2017. Serotonin enhances excitability and gamma frequency temporal integration in mouse prefrontal fast-spiking interneurons. *eLife*, 6, e31991.
- AZIMI, Z., BARZAN, R., SPOIDA, K., SURDIN, T., WOLLENWEBER, P., MARK, M. D., HERLITZE, S. & JANCKE, D. 2020. Separable gain control of ongoing and evoked activity in the visual cortex by serotonergic input. *eLife*, 9, e53552.
- BARTHÓ, P., HIRASE, H., MONCONDUIT, L., ZUGARO, M., HARRIS, K. D. & BUZSÁKI, G. 2004. Characterization of neocortical principal cells and interneurons by network interactions and extracellular features. *J Neurophysiol*, 92, 600-8.
- CARHART-HARRIS, R. L. & FRISTON, K. J. 2019. REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics. *Pharmacol Rev*, 71, 316-344.
- CARHART-HARRIS, R. L., MUTHUKUMARASWAMY, S., ROSEMAN, L., KAELEN, M., DROOG, W., MURPHY, K., TAGLIAZUCCHI, E., SCHENBERG, E. E., NEST, T., ORBAN, C., LEECH, R., WILLIAMS, L. T., WILLIAMS, T. M., BOLSTRIDGE, M., SESSA, B., MCGONIGLE, J., SERENO, M. I., NICHOLS, D., HELLYER, P. J., HOB DEN, P., EVANS, J., SINGH, K. D., WISE, R. G., CURRAN, H. V., FEILDING, A. & NUTT, D. J. 2016. Neural correlates of the LSD experience revealed by multimodal neuroimaging. *Proc Natl Acad Sci U S A*, 113, 4853-8.
- CHALMERS, D. T. & WATSON, S. J. 1991. Comparative anatomical distribution of 5-HT<sub>1A</sub> receptor mRNA and 5-HT<sub>1A</sub> binding in rat brain--a combined in situ hybridisation/in vitro receptor autoradiographic study. *Brain Res*, 561, 51-60.
- CHEN, N., SUGIHARA, H. & SUR, M. 2015. An acetylcholine-activated microcircuit drives temporal dynamics of cortical activity. *Nat Neurosci*, 18, 892-902.
- DE BLASI, S., CIBA, M., BAHMER, A. & THIELEMANN, C. 2019. Total spiking probability edges: A cross-correlation based method for effective connectivity estimation of cortical spiking neurons. *J Neurosci Methods*, 312, 169-181.



- 762 DESCARRIES, L., RIAD, M. & PARENT, M. 2010. CHAPTER 1.4 - Ultrastructure of the  
763 Serotonin Innervation in the Mammalian Central Nervous System. *In*: MÜLLER, C. P.  
764 & JACOBS, B. L. (eds.) *Handbook of Behavioral Neuroscience*. Elsevier.
- 765 FANSELOW, E. E., RICHARDSON, K. A. & CONNORS, B. W. 2008. Selective, state-  
766 dependent activation of somatostatin-expressing inhibitory interneurons in mouse  
767 neocortex. *J Neurophysiol*, 100, 2640-52.
- 768 FREI, E., GAMMA, A., PASCUAL-MARQUI, R., LEHMANN, D., HELL, D. & VOLLENWEIDER,  
769 F. X. 2001. Localization of MDMA-induced brain activity in healthy volunteers using  
770 low resolution brain electromagnetic tomography (LORETA). *Hum Brain Mapp*, 14,  
771 152-65.
- 772 FUNK, C. M., PEELMAN, K., BELLESI, M., MARSHALL, W., CIRELLI, C. & TONONI, G.  
773 2017. Role of Somatostatin-Positive Cortical Interneurons in the Generation of Sleep  
774 Slow Waves. *J Neurosci*, 37, 9132-9148.
- 775 GIBSON, J. R., BEIERLEIN, M. & CONNORS, B. W. 1999. Two networks of electrically  
776 coupled inhibitory neurons in neocortex. *Nature*, 402, 75-9.
- 777 GRANDJEAN, J., CORCOBA, A., KAHN, M. C., UPTON, A. L., DENERIS, E. S., SEIFRITZ, E.,  
778 HELMCHEN, F., MANN, E. O., RUDIN, M. & SAAB, B. J. 2019. A brain-wide  
779 functional map of the serotonergic responses to acute stress and fluoxetine. *Nat*  
780 *Commun*, 10, 350.
- 781 GREEN, A. R., MECHAN, A. O., ELLIOTT, J. M., O'SHEA, E. & COLADO, M. I. 2003. The  
782 Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine  
783 (MDMA, "Ecstasy"). *Pharmacological Reviews*, 55, 463-508.
- 784 HARDEBO, J. E. & OWMAN, C. 1980. Barrier mechanisms for neurotransmitter monoamines  
785 and their precursors at the blood-brain interface. *Ann Neurol*, 8, 1-31.
- 786 HARDY, A., PALOUZIER-PAULIGNAN, B., DUCHAMP, A., ROYET, J. P. & DUCHAMP-  
787 VIRET, P. 2005. 5-Hydroxytryptamine action in the rat olfactory bulb: in vitro  
788 electrophysiological patch-clamp recordings of juxtaglomerular and mitral cells.  
789 *Neuroscience*, 131, 717-31.
- 790 HARRIS, K. D. & THIELE, A. 2011. Cortical state and attention. *Nat Rev Neurosci*, 12, 509-  
791 23.
- 792 HAYES, D. J. & GREENSHAW, A. J. 2011. 5-HT receptors and reward-related behaviour: a  
793 review. *Neurosci Biobehav Rev*, 35, 1419-49.
- 794 HITZ, C., STEUBER-BUCHBERGER, P., DELIC, S., WURST, W. & KUHN, R. 2009.  
795 Generation of shRNA transgenic mice. *Methods Mol Biol*, 530, 101-29.
- 796 HITZ, C., WURST, W. & KUHN, R. 2007. Conditional brain-specific knockdown of MAPK  
797 using Cre/loxP regulated RNA interference. *Nucleic Acids Res*, 35, e90.
- 798 KAUR, S., JUNEK, A., BLACK, M. A. & SEMBA, K. 2008. Effects of ibotenate and 192IgG-  
799 saporin lesions of the nucleus basalis magnocellularis/substantia innominata on  
800 spontaneous sleep and wake states and on recovery sleep after sleep deprivation in  
801 rats. *J Neurosci*, 28, 491-504.

802 KOMETER, M., POKORNY, T., SEIFRITZ, E. & VOLLEINWEIDER, F. X. 2015. Psilocybin-  
803 induced spiritual experiences and insightfulness are associated with synchronization  
804 of neuronal oscillations. *Psychopharmacology (Berl)*, 232, 3663-76.

805 KUYPERS, K. P. C., DE LA TORRE, R., FARRE, M., PIZARRO, N., XICOTA, L. &  
806 RAMAEKERS, J. G. 2018. MDMA-induced indifference to negative sounds is  
807 mediated by the 5-HT<sub>2A</sub> receptor. *Psychopharmacology (Berl)*, 235, 481-490.

808 KVITSIANI, D., RANADE, S., HANGYA, B., TANIGUCHI, H., HUANG, J. Z. & KEPECS, A.  
809 2013. Distinct behavioural and network correlates of two interneuron types in  
810 prefrontal cortex. *Nature*, 498, 363-6.

811 LANSBERGEN, M. M., DUMONT, G. J. H., VAN GERVEN, J. M. A., BUITELAAR, J. K. &  
812 VERKES, R.-J. 2011. Acute effects of MDMA (3,4-methylenedioxymethamphetamine)  
813 on EEG oscillations: alone and in combination with ethanol or THC (delta-9-  
814 tetrahydrocannabinol). *Psychopharmacology*, 213, 745-756.

815 LEE, S. H. & DAN, Y. 2012. Neuromodulation of brain states. *Neuron*, 76, 209-22.

816 LIECHTI, M. E., SAUR, M. R., GAMMA, A., HELL, D. & VOLLENWEIDER, F. X. 2000.  
817 Psychological and Physiological Effects of MDMA ("Ecstasy") after Pretreatment with  
818 the 5-HT<sub>2</sub> Antagonist Ketanserin in Healthy Humans. *Neuropsychopharmacology*, 23,  
819 396-404.

820 LIN, L. C. & SIBILLE, E. 2015. Somatostatin, neuronal vulnerability and behavioral  
821 emotionality. *Mol Psychiatry*, 20, 377-87.

822 LOTTEM, E., LÖRINCZ, M. L. & MAINEN, Z. F. 2016. Optogenetic Activation of Dorsal  
823 Raphe Serotonin Neurons Rapidly Inhibits Spontaneous But Not Odor-Evoked  
824 Activity in Olfactory Cortex. *J Neurosci*, 36, 7-18.

825 MAREK, G. J. & AGHAJANIAN, G. K. 1994. Excitation of interneurons in piriform cortex by  
826 5-hydroxytryptamine: blockade by MDL 100,907, a highly selective 5-HT<sub>2A</sub> receptor  
827 antagonist. *Eur J Pharmacol*, 259, 137-41.

828 MAREK, G. J., CARPENTER, L. L., MCDUGGLE, C. J. & PRICE, L. H. 2003. Synergistic  
829 action of 5-HT<sub>2A</sub> antagonists and selective serotonin reuptake inhibitors in  
830 neuropsychiatric disorders. *Neuropsychopharmacology*, 28, 402-12.

831 MARTIN, D. A. & NICHOLS, C. D. 2016. Psychedelics Recruit Multiple Cellular Types and  
832 Produce Complex Transcriptional Responses Within the Brain. *EBioMedicine*, 11,  
833 262-277.

834 MCGINTY, D. J. & HARPER, R. M. 1976. Dorsal raphe neurons: depression of firing during  
835 sleep in cats. *Brain Research*, 101, 569-575.

836 MELTZER, H. Y. 1999. The role of serotonin in antipsychotic drug action.  
837 *Neuropsychopharmacology*, 21, 106s-115s.

838 MICHAEL, A. M., PARKER, P. R. L. & NIELL, C. M. 2019. A Hallucinogenic Serotonin-2A  
839 Receptor Agonist Reduces Visual Response Gain and Alters Temporal Dynamics in  
840 Mouse V1. *Cell Rep*, 26, 3475-3483.e4.

841 MONTI, J. M. 2011. Serotonin control of sleep-wake behavior. *Sleep Med Rev*, 15, 269-81.

842 MURAYAMA, M., PÉREZ-GARCÍA, E., NEVIAN, T., BOCK, T., SENN, W. & LARKUM, M. E.  
843 2009. Dendritic encoding of sensory stimuli controlled by deep cortical interneurons.  
844 *Nature*, 457, 1137-1141.

845 MUTHUKUMARASWAMY, S. D., CARHART-HARRIS, R. L., MORAN, R. J., BROOKES, M.  
846 J., WILLIAMS, T. M., ERRTIZOE, D., SESSA, B., PAPADOPOULOS, A.,  
847 BOLSTRIDGE, M., SINGH, K. D., FEILDING, A., FRISTON, K. J. & NUTT, D. J. 2013.  
848 Broadband cortical desynchronization underlies the human psychedelic state. *J*  
849 *Neurosci*, 33, 15171-83.

850 MUZERELLE, A., SCOTTO-LOMASSESE, S., BERNARD, J. F., SOIZA-REILLY, M. &  
851 GASPARD, P. 2016. Conditional anterograde tracing reveals distinct targeting of  
852 individual serotonin cell groups (B5–B9) to the forebrain and brainstem. *Brain*  
853 *Structure and Function*, 221, 535-561.

854 NAKAI, N., NAGANO, M., SAITOW, F., WATANABE, Y., KAWAMURA, Y., KAWAMOTO, A.,  
855 TAMADA, K., MIZUMA, H., ONOE, H., WATANABE, Y., MONAI, H., HIRASE, H.,  
856 NAKATANI, J., INAGAKI, H., KAWADA, T., MIYAZAKI, T., WATANABE, M., SATO, Y.,  
857 OKABE, S., KITAMURA, K., KANO, M., HASHIMOTO, K., SUZUKI, H. & TAKUMI, T.  
858 2017. Serotonin rebalances cortical tuning and behavior linked to autism symptoms  
859 in 15q11-13 CNV mice. *Sci Adv*, 3, e1603001.

860 NESKE, G. T. 2015. The Slow Oscillation in Cortical and Thalamic Networks: Mechanisms  
861 and Functions. *Front Neural Circuits*, 9, 88.

862 NESKE, G. T., PATRICK, S. L. & CONNORS, B. W. 2015. Contributions of diverse excitatory  
863 and inhibitory neurons to recurrent network activity in cerebral cortex. *J Neurosci*, 35,  
864 1089-105.

865 NICHOLS, D. E. 2016. Psychedelics. *Pharmacol Rev*, 68, 264-355.

866 NICHOLS, D. E. & NICHOLS, C. D. 2008. Serotonin Receptors. *Chemical Reviews*, 108,  
867 1614-1641.

868 NIETHARD, N., NGO, H. V., EHRLICH, I. & BORN, J. 2018. Cortical circuit activity underlying  
869 sleep slow oscillations and spindles. *Proc Natl Acad Sci U S A*, 115, E9220-e9229.

870 OBERMAYER, J., HEISTEK, T. S., KERKHOF, A., GORIOUNOVA, N. A., KROON, T.,  
871 BAAYEN, J. C., IDEMA, S., TESTA-SILVA, G., COUEY, J. J. & MANSVELDER, H. D.  
872 2018. Lateral inhibition by Martinotti interneurons is facilitated by cholinergic inputs in  
873 human and mouse neocortex. *Nat Commun*, 9, 4101.

874 OIKONOMOU, G., ALTERMATT, M., ZHANG, R. W., COUGHLIN, G. M., MONTZ, C.,  
875 GRADINARU, V. & PROBER, D. A. 2019. The Serotonergic Raphe Promote Sleep in  
876 Zebrafish and Mice. *Neuron*, 103, 686-701.e8.

877 PANTAZOPOULOS, H., WISEMAN, J. T., MARKOTA, M., EHRENFELD, L. & BERRETTA, S.  
878 2017. Decreased Numbers of Somatostatin-Expressing Neurons in the Amygdala of  
879 Subjects With Bipolar Disorder or Schizophrenia: Relationship to Circadian Rhythms.  
880 *Biol Psychiatry*, 81, 536-547.

PETZOLD, G. C., HAGIWARA, A. & MURTHY, V. N. 2009. Serotonergic modulation of odor input to the mammalian olfactory bulb. *Nature Neuroscience*, 12, 784-791.

PRELLER, K. H., BURT, J. B., JI, J. L., SCHLEIFER, C. H., ADKINSON, B. D., STAMPFLI, P., SEIFRITZ, E., REPOVS, G., KRYSTAL, J. H., MURRAY, J. D., VOLLENWEIDER, F. X. & ANTICEVIC, A. 2018. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT<sub>2A</sub> receptor. *Elife*, 7.

PUIG, M. V., WATAKABE, A., USHIMARU, M., YAMAMORI, T. & KAWAGUCHI, Y. 2010. Serotonin modulates fast-spiking interneuron and synchronous activity in the rat prefrontal cortex through 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptors. *J Neurosci*, 30, 2211-22.

RANGANATHAN, G. N., APOSTOLIDES, P. F., HARNETT, M. T., XU, N. L., DRUCKMANN, S. & MAGEE, J. C. 2018. Active dendritic integration and mixed neocortical network representations during an adaptive sensing behavior. *Nat Neurosci*, 21, 1583-1590.

RENART, A., DE LA ROCHA, J., BARTHO, P., HOLLENDER, L., PARGA, N., REYES, A. & HARRIS, K. D. 2010. The asynchronous state in cortical circuits. *Science*, 327, 587-90.

ROTHMAN, R. B. & BAUMANN, M. H. 2002. Therapeutic and adverse actions of serotonin transporter substrates. *Pharmacol Ther*, 95, 73-88.

ROUX, L., STARK, E., SJULSON, L. & BUZSAKI, G. 2014. In vivo optogenetic identification and manipulation of GABAergic interneuron subtypes. *Curr Opin Neurobiol*, 26, 88-95.

SANCHEZ-VIVES, M. V., MASSIMINI, M. & MATTIA, M. 2017. Shaping the Default Activity Pattern of the Cortical Network. *Neuron*, 94, 993-1001.

SCHMITZ, D., GLOVELI, T., EMPSON, R. M., DRAGUHN, A. & HEINEMANN, U. 1998. Serotonin reduces synaptic excitation in the superficial medial entorhinal cortex of the rat via a presynaptic mechanism. *J Physiol*, 508 ( Pt 1), 119-29.

SCHNUTGEN, F., DOERFLINGER, N., CALLEJA, C., WENDLING, O., CHAMBON, P. & GHYSELINCK, N. B. 2003. A directional strategy for monitoring Cre-mediated recombination at the cellular level in the mouse. *Nat Biotechnol*, 21, 562-5.

SEILLIER, L., LORENZ, C., KAWAGUCHI, K., OTT, T., NIEDER, A., POURRIAH, P. & NIENBORG, H. 2017. Serotonin Decreases the Gain of Visual Responses in Awake Macaque V1. *J Neurosci*, 37, 11390-11405.

SENZAI, Y., FERNANDEZ-RUIZ, A. & BUZSAKI, G. 2019. Layer-Specific Physiological Features and Interlaminar Interactions in the Primary Visual Cortex of the Mouse. *Neuron*, 101, 500-513 e5.

SHAMASH, P., CARANDINI, M., HARRIS, K. & STEINMETZ, N. 2018. A tool for analyzing electrode tracks from slice histology. *bioRxiv*, 447995.

SHELDON, P. W. & AGHAJANIAN, G. K. 1990. Serotonin (5-HT) induces IPSPs in pyramidal layer cells of rat piriform cortex: evidence for the involvement of a 5-HT<sub>2</sub>-activated interneuron. *Brain Res*, 506, 62-9.

- 921 SIPPY, T. & YUSTE, R. 2013. Decorrelating action of inhibition in neocortical networks. *J*  
922 *Neurosci*, 33, 9813-30.
- 923 SMITH, S. L., SMITH, I. T., BRANCO, T. & HÄUSSER, M. 2013. Dendritic spikes enhance  
924 stimulus selectivity in cortical neurons in vivo. *Nature*, 503, 115-120.
- 925 STERIADE, M., NUNEZ, A. & AMZICA, F. 1993. A novel slow (< 1 Hz) oscillation of  
926 neocortical neurons in vivo: depolarizing and hyperpolarizing components. *J*  
927 *Neurosci*, 13, 3252-65.
- 928 STRINGER, C., PACHITARIU, M., STEINMETZ, N. A., OKUN, M., BARTHO, P., HARRIS, K.  
929 D., SAHANI, M. & LESICA, N. A. 2016. Inhibitory control of correlated intrinsic  
930 variability in cortical networks. *Elife*, 5.
- 931 STURGILL, J. F. & ISAACSON, J. S. 2015. Somatostatin cells regulate sensory response  
932 fidelity via subtractive inhibition in olfactory cortex. *Nat Neurosci*, 18, 531-5.
- 933 TAHVILDARI, B., WOLFEL, M., DUQUE, A. & MCCORMICK, D. A. 2012. Selective functional  
934 interactions between excitatory and inhibitory cortical neurons and differential  
935 contribution to persistent activity of the slow oscillation. *J Neurosci*, 32, 12165-79.
- 936 TAKAHASHI, N., OERTNER, T. G., HEGEMANN, P. & LARKUM, M. E. 2016. Active cortical  
937 dendrites modulate perception. *Science*, 354, 1587-1590.
- 938 TANG, Z.-Q. & TRUSSELL, L. O. 2017. Serotonergic Modulation of Sensory Representation  
939 in a Central Multisensory Circuit Is Pathway Specific. *Cell reports*, 20, 1844-1854.
- 940 TANIGUCHI, H., HE, M., WU, P., KIM, S., PAIK, R., SUGINO, K., KVITSIANI, D., FU, Y., LU,  
941 J., LIN, Y., MIYOSHI, G., SHIMA, Y., FISHELL, G., NELSON, S. B. & HUANG, Z. J.  
942 2011. A resource of Cre driver lines for genetic targeting of GABAergic neurons in  
943 cerebral cortex. *Neuron*, 71, 995-1013.
- 944 TEIXEIRA, C. M., ROSEN, Z. B., SURI, D., SUN, Q., HERSH, M., SARGIN, D., DINCHEVA, I.,  
945 MORGAN, A. A., SPIVACK, S., KROK, A. C., HIRSCHFELD-STOLER, T., LAMBE, E.  
946 K., SIEGELBAUM, S. A. & ANSORGE, M. S. 2018. Hippocampal 5-HT Input  
947 Regulates Memory Formation and Schaffer Collateral Excitation. *Neuron*, 98, 992-  
948 1004.e4.
- 949 TRAINITO, C., VON NICOLAI, C., MILLER, E. K. & SIEGEL, M. 2019. Extracellular Spike  
950 Waveform Dissociates Four Functionally Distinct Cell Classes in Primate Cortex. *Curr*  
951 *Biol*.
- 952 TREMBLAY, R., LEE, S. & RUDY, B. 2016. GABAergic Interneurons in the Neocortex: From  
953 Cellular Properties to Circuits. *Neuron*, 91, 260-92.
- 954 TURRIGIANO, G. 2011. Too many cooks? Intrinsic and synaptic homeostatic mechanisms in  
955 cortical circuit refinement. *Annu Rev Neurosci*, 34, 89-103.
- 956 UNDERWOOD, M. D., KASSIR, S. A., BAKALIAN, M. J., GALFALVY, H., DWORK, A. J.,  
957 MANN, J. J. & ARANGO, V. 2018. Serotonin receptors and suicide, major depression,  
958 alcohol use disorder and reported early life adversity. *Translational Psychiatry*, 8, 279.



- 959 UPHOUSE, L. & GUPTARAK, J. 2010. Serotonin and sexual behavior. *Handbook of the*  
960 *behavioral neurobiology of serotonin*. San Diego, CA, US: Elsevier Academic Press.
- 961 URBAN-CIECKO, J., FANSELOW, E. E. & BARTH, A. L. 2015. Neocortical somatostatin  
962 neurons reversibly silence excitatory transmission via GABA<sub>B</sub> receptors. *Curr Biol*, 25,  
963 722-31.
- 964 VAN STRIEN, N. M., CAPPAERT, N. L. & WITTER, M. P. 2009. The anatomy of memory: an  
965 interactive overview of the parahippocampal-hippocampal network. *Nat Rev*  
966 *Neurosci*, 10, 272-82.
- 967 VANDERWOLF, C. H. & BAKER, G. B. 1986. Evidence that serotonin mediates non-  
968 cholinergic neocortical low voltage fast activity, non-cholinergic hippocampal  
969 rhythmical slow activity and contributes to intelligent behavior. *Brain Res*, 374, 342-  
970 56.
- 971 WILSON, N. R., RUNYAN, C. A., WANG, F. L. & SUR, M. 2012. Division and subtraction by  
972 distinct cortical inhibitory networks in vivo. *Nature*, 488, 343-348.
- 973 WOOD, J., KIM, Y. & MOGHADDAM, B. 2012. Disruption of prefrontal cortex large scale  
974 neuronal activity by different classes of psychotomimetic drugs. *J Neurosci*, 32,  
975 3022-31.
- 976 WYSKIEL, D. R. & ANDRADE, R. 2016. Serotonin excites hippocampal CA1 GABAergic  
977 interneurons at the stratum radiatum-stratum lacunosum moleculare border.  
978 *Hippocampus*, 26, 1107-14.
- 979 ZHOU, F.-M. & HABLITZ, J. J. 1999. Activation of Serotonin Receptors Modulates Synaptic  
980 Transmission in Rat Cerebral Cortex. *Journal of Neurophysiology*, 82, 2989-2999.

981